The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-11. Anything still debated is marked as such rather than presented as settled.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
== External links == Gerngross TU, Slater SC (August 2000). "How green are green plastics?". Sci. Am. 283 (2): 37–41. Bibcode:2000SciAm.283b..36G. doi:10.1038/scientificamerican0800-36. PMID 10914397. Plastics from plants called costly (CNN) Tillman Gerngross Faculty Page at Dartmouth About Adimab LLC.
== Etymology and history == From the Greek words baeo (little) and kystis (bladder) 1945 P. baeocystis is first collected in Eugene, Oregon. 1958 P. baeocystis is formally described and published by Singer and Smith. 1962 Psilocin is first reported in this species. 1967-68 Baeocystin and norbaeocystin are discovered and named. 1981 Testing again reveals psilocybin, psilocin, baeocystin and norbaeocystin.
The eIF4F complex supports the cap-dependent translation initiation process and is composed of the initiation factors eIF4A, eIF4E, and eIF4G. The cap end of the mRNA, being the 5’ end, is brought to the complex where the 43S ribosomal complex can bind and scan the mRNA for the start codon. During this process, the 60S ribosomal subunit binds and the large 80S ribosomal complex is formed. The eIF4G plays a role, as it interacts with the polyA-binding protein, attracting the mRNA. The eIF4E then binds the cap of the mRNA and the small ribosomal subunit binds to the eIF4G to begin the process of creating the 80S ribosomal complex. The eIF4A works to make this process more successful, as it is a DEAD box helicase. It allows for the unwinding of the untranslated regions of the mRNA to allow for ribosomal binding and scanning.
Droplet countercurrent chromatography (DCCC or DCC) was introduced in 1970 by Tanimura, Pisano, Ito, and Bowman. DCCC is considered to be a form of liquid-liquid separation, which includes countercurrent distribution and countercurrent chromatography, that employs a liquid stationary phase held in a collection of vertical glass columns connected in series. The mobile phase passes through the columns in the form of droplets. The DCCC apparatus may be run with the lower phase stationary and the upper phase being introduced to the bottom of each column. Or it may be run with the upper phase stationary and the lower phase being introduced from the top of the column. In both cases, the work of gravity is allowed influence the two immiscible liquids of different densities to form the signature droplets that rise or descend through the column. The mobile phase is pumped at a rate that will allow droplets to form that maximize the mass transfer of a compound between the upper and lower phases. Compounds that are more soluble in the upper phase will travel quickly through the column, while compounds that are more soluble in the stationary phase will linger. Separation occurs because different compounds distribute differently, in a ratio called the partition coefficient, between the two phases. The biphasic solvent system must be carefully formulated so that it will perform appropriately in the DCCC column. The solvent system must form two phases without excess emulsification in order to form droplets.
=== Argentina === The president of the Justicialist Party (and former Argentine president), Cristina Fernández de Kirchner, criticized the strikes, labelling Maduro's capture as "kidnapping" and stated that Trump "crossed the line again".
Sources: en.wikipedia.org
Numerous species of hagfish feed on carrion, including Atlantic hagfish, black hagfish, blueband hagfish, Pacific hagfish, slender hagfish and whiteface hagfish. Types of carrion eaten include dead whales, hake, mackerel, pilchards and jellyfish, as well as fishery discards of whiting and langoustine. Hagfish are highly adapted to carrion feeding. For example, they are able to survive extended periods without eating and can detect carrion from long distances. Hagfish are also highly mobile and can arrive at carcasses within minutes or hours of an animal’s death. Immune defenses such as lysozyme-containing slime and antimicrobial proteins (e.g. myxinidin) are thought to protect hagfish from microbial pathogens.
Motorsport Space travel Sports equipment Sailing Orthopedic technology in orthotics as well as in prosthetics In electrical engineering as an "intermediate layer" in multilayer circuit boards and as insulating material for electrical machines and transformers Rotor blades in wind turbines
Some criminal syndicates have been known to hold their own "trials" for members of theirs who had been accused of wrongdoing; the punishments that the accused member would face if "found guilty" would vary depending on the offense.
== Symbol encoding in character sets == The official symbol for the SI prefix micro is a Greek lowercase mu (μ). For reasons stemming from its design, Unicode has two different character codes for the letter, with slightly different appearance in some computer fonts, although most fonts use the same glyph. U+03BC μ GREEK SMALL LETTER MU is in the Greek range. According to The Unicode Consortium, the Greek letter character is preferred, but implementations must recognize the micro sign as well, for compatibility with legacy character sets. This distinction also occurs in some legacy code pages, notably Windows-1253. In circumstances in which only the Latin alphabet is available, ISO 2955 (since 1974, withdrawn 2001), DIN 66030 (since 1980) and BS 6430 (since 1983) allow the prefix μ to be substituted by the letter ⟨u⟩ (U+0075 u LATIN SMALL LETTER U) as, for example, in um for μm, or uF for μF . Similarly, capacitor values according to the RKM code defined in IEC 60062 (since 1952) can be written as 4u7 (or 4U7) instead of 4μ7 if the Greek letter μ is not available. The CJK Compatibility block contains square forms of some Japanese katakana measure and currency units. U+3343 ㍃ SQUARE MAIKURO corresponds to マイクロ maikuro.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.